Cases & Deals

  • Home
  • Practices
  • Hookipa successfully defends its tri-segmented arenavirus platform technology patent in EPO opposition proceedings

Share

Hookipa successfully defends its tri-segmented arenavirus platform technology patent in EPO opposition proceedings

May 2023

Client(s) Hookipa Biotech GmbH

Jones Day successfully defended Hookipa Biotech GmbH in opposition proceedings at the European Patent Office. Hookipa's in-licensed patent EP 3218504 is directed to a tri-segmented arenavirus platform technology useful in a wide range of immunotherapies and vaccines against cancer and infectious diseases.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.